Digital health company Better Therapeutics has the FDA approval for lead digital therapeutic (DTx) AspyreRx for type 2 diabetes it was hoping for – but now it has to conve
Digital health company Better Therapeutics has submitted its lead prescription digital therapeutic (DTx) BT-001 to the FDA, seeking approval for use by adults with type 2 diabetes (T2D).
Better Therapeutics has joined the ranks of publicly-listed digital health companies after completing a merger with blank cheque company Mountain Crest Acquisition Corp II.
After announcing plans to go public, prescription digital therapeutics (DTx) firm Better Therapeutics has begun a “real world” study to test whether its BT-001 prescription cognitive behavi
An intriguing new study has suggested that there could be a correlation between the built environment of an area – its buildings, streets and green spaces – and the risk o